InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
-9.4%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Pilnik Richard D., Director. Director active across 1 company, notably DiaMedica Therapeutics Inc.. In total, 10 disclosures have been logged. Breakdown: 4 buys · 0 sell. Total volume traded: €197k. History available since 16 August 2021. The latest transaction was disclosed on 7 April 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations10 total
24,000 shares@ US$2.117.7% of flowVoting Common Shares, no par value per shareSEC:0001760016-25-000004:0
10,393 shares@ US$5.348.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000002:0
30,357 shares@ US$2.8012.8% of flowVoting Common Shares, no par value per shareSEC:0001235802-24-000003:0
38,363 shares@ US$3.9122.7% of flowVoting Common Shares, no par value per shareSEC:0001235802-23-000068:0
Ideal exit: 19 Mar 2024 (T+270)
55,555 shares@ US$1.5313.2% of flowVoting Common Shares, no par value per shareSEC:0001235802-23-000001:0
35,000 shares@ US$1.38557.6% of flowVoting Common Shares, no par value per shareSEC:0001235802-22-000130:0
Ideal exit: 1 Sept 2023 (T+270)
23,762 shares@ US$3.580.018% mcap45.8% of flowVoting Common Shares, no par value per shareSEC:0001235802-22-000003:0
23,762 shares@ US$3.5812.4% of flowVoting Common Shares, no par value per shareSEC:0001235802-22-000003
2,500 shares@ US$3.21260.0016% mcap4.2% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000100:0
Ideal exit: 13 May 2022 (T+270)
2,500 shares@ US$3.21261.1% of flowVoting Common Shares, no par value per shareSEC:0001235802-21-000100
Ideal exit: 13 May 2022 (T+270)
10 of 10 declarations
About Pilnik Richard D.
Richard D. Pilnik is a Director at DiaMedica Therapeutics Inc. He brings his expertise in corporate governance and strategy. Richard plays an active role in overseeing the operations and strategic decisions, contributing to the achievement of the company's goals.
